Choose Your Country or Region

Colorectal Cancer

Modeling Agent

Dextran sulfate sodium

Drugs Approved

Irinotecan hydrochloride

Calcium folinate

Tipiracil hydrochloride

Chemotherapy Regimens

CAPOX: Capecitabine; Oxaliplatin

FOLFIRI: Calcium folinate; 5-FU; Irinotecan hydrochloride

FOLFIRI-BEVACIZUMAB: Calcium folinate; 5-FU; Irinotecan hydrochloride; Bevacizumab

FOLFIRI-CETUXIMAB: Calcium folinate; 5-FU; Irinotecan hydrochloride; Cetuximab

FOLFOX: Calcium folinate; 5-FU; Oxaliplatin

FU-LV: 5-FU; Calcium folinate

XELIRI: Capecitabine; Irinotecan hydrochloride

XELOX: Capecitabine; Oxaliplatin

FOLFIRINOX: Calcium folinate; 5-FU; Irinotecan hydrochloride; Oxaliplatin

NCCN Guidelines Recommendations ^[1]

First-Line Treatment: Calcium folinate; Capecitabine; Bevacizumab; Panitumumab; Cetuximab

Second-Line Treatment: Panitumumab; Nivolumab; Ipilimumab; Dostarlimab; Trastuzumab; Lapatinib; Trastuzumab-deruxtecan

Third-Line Treatment: Trifluridine; Tipiracil hydrochloride

ICIs

PD-1: Balstilimab; Finotonlimab; Nivolumab; Ezabenlimab; Retifanlimab; Toripalimab; Tislelizumab; Serplulimab; Zimberelimab; Penpulimab; Sintilimab; Pembrolizumab; Spartalizumab; Budigalimab; Pidilizumab

PD-L1: Atezolizumab; Durvalumab; Avelumab; Adebrelimab; Sugemalimab

CTLA-4: Nurulimab; Zalifrelimab; Quavonlimab; Ipilimumab; Tremelimumab

Anti-Angiogenesis

mAbs: Bevacizumab; Ramucirumab; Panitumumab

TKIs: Masitinib; Fruquintinib; Regorafenib; Apatinib; Cabozantinib

Targeted Therapy (A) ^[2]

EGFR: Necitumumab; Panitumumab; Nimotuzumab; Cetuximab; Demupitamab; Modotuximab; Pimurutamab; Imgatuzumab; Matuzumab; Zalutumumab

VEGF-A: Bevacizumab

TYMS: Varisacumab; Capecitabine; Raltitrexed; Floxuridine; 5-FU; Folinic acid

TOP1: Irinotecan hydrochloride; SN-38; Rubitecan

KRAS G12C: Adagrasib; Sotorasib; Opnurasib; LY3537982; Divarasib

Tubulin: Paclitaxel; Verubulin hydrochloride; ABT-751

CEACAM5: Labetuzumab; Labetuzumab govitecan

Targeted Therapy (B) ^[2]

DNA: TMZ; Oxaliplatin; Lurbinectedin; Nimustine Hydrochloride; TRC102

HER2: Trastuzumab; Tucatinib; TAS0728

BRAF: Encorafenib

KRAS G12D: MRTX1133

VEGFR2: Semaxanib; Apatinib; Ramucirumab

ERK1/2: SCH772984; Ravoxertinib; Ulixertinib; Temuterkib; ASN007; MK-8353

SHP2: SHP099 HCl; Batoprotafib; RMC-4550; NSC87877

CSCs Marker ^[3]

Lgr5: Petosemtamab

EpCAM: Adecatumumab; Citatuzumab; Oportuzumab

Bmi1: PRT4165; PTC-209 HBr; PTC-028; Unesbulin

CD44: Bivatuzumab; Angstrom6

CD26: Begelomab

ALDH1: Disulfiram; NCT-501; CM10

Compound Library

FDA-approved Anticancer Drug Library

Anti-cancer Compound Library

Anti-cancer Compound Library-Ⅱ

Anti-cancer Metabolism Compound Library

Cambridge Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Tyrosine Kinase Inhibitor Library

Angiogenesis Related compound Library

References

https://www.nccn.org/patients/guidelines/content/PDF/colon-patient.pdf
https://synapse.zhihuiya.com/drug-list?query_id=3b3cb0c7-afda-4358-aa04-ecde3168fbc3&tab=table
http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/abstract/abstract12046.shtml